Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TriNav Device for TACE in HCC
NCT02853500Phase 4Withdrawn
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Jul 2016
- Primary completion
- Feb 2025
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial (2 arms), sponsored by Dana-Farber Cancer Institute. Primary endpoint: Capillary permeability at 2 years. Planned start Jul 2016; status: withdrawn.
Beyond the preview
Go deeper on NCT02853500.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02853500.